 | Up a level |
Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press
Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genné, D; Nüesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; ... (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, 368(9534), pp. 459-65. London: Elsevier 10.1016/S0140-6736(06)69153-8
Karrer, U; Ledergerber, B; Furrer, H; Elzi, L; Battegay, M; Cavassini, M; Gayet-Ageron, A; Hirschel, B; Schmid, P; Russotti, M; Weber, R; Speck, RF; Swiss, HIV Cohort Study (2005). Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS, 19(17), pp. 1987-94. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000194136.73876.9c
